Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 199

Results For "CRE"

4448 News Found

Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery
News | March 16, 2024

Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery

More than 10,000 scientific publications containing EUDRAGIT


Bayer and Aignostics to collaborate on next generation precision oncology
News | March 16, 2024

Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development


Abbott India appointed Swati Dalal as MD
People | March 16, 2024

Abbott India appointed Swati Dalal as MD

Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager


Zydus launches generic version of Olaparib ‘IBYRA’ in India
News | March 14, 2024

Zydus launches generic version of Olaparib ‘IBYRA’ in India

The drug will target specific genetic mutations prevalent in certain types of cancers


Cureskin secures US$ 20 million in Series B funding
News | March 14, 2024

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India


Evonik establishes a new research institute dedicated to skin sciences
News | March 13, 2024

Evonik establishes a new research institute dedicated to skin sciences

New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs


Venus Remedies gets huge global acclaim with UNICEF GMP approval
News | March 12, 2024

Venus Remedies gets huge global acclaim with UNICEF GMP approval

Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF


USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
Biotech | March 12, 2024

USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy

It is the first autotaxin inhibitor to be investigated in cancer patients